tubacin profile

tubacin: inhibits histone deacetylase 6; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6675804
CHEMBL ID	356769
CHEBI ID	94166
SCHEMBL ID	4741166
MeSH ID	M0449941

Synonym
tubacin
n-(4-{(2r,4r,6s)-4-{[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanyl]methyl}-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl}phenyl)-n -hydroxyoctanediamide
chembl356769 ,
bdbm22449
DIOX-H_003551
AC1O7Y2P ,
n-[4-[(2r,4r,6s)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-n'-hydroxyoctanediamide
octanediamide, n1-(4-((2r,4r,6s)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-n8-hydroxy-, rel-
537049-40-4
n1-[4-[(2r,4r,6s)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-n8-hydroxy-octanediamide
NCGC00346840-01
rel-n1-(4-((2r,4r,6s)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-n8-hydroxyoctanediamide
S2239
c41h43n3o7s
n1-(4-((2r,4r,6s)-4-(((4,5-diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-n8-hydroxyoctanediamide
n-[4-[(2r,4r,6s)-4-[[4,5-di(phenyl)-1,3-oxazol-2-yl]sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-n'-hydroxyoctanediamide
BRD-K98426715-001-01-9
gtpl7374
02c2g1d30d ,
unii-02c2g1d30d
SCHEMBL4741166
1350555-93-9
n-[4-[(2r,4r,6s)-4-[[(4,5-diphenyl- 2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl ]-1,3-dioxan-2-yl]phenyl]-n'-hydroxyoctanediamide
HB1403
AC-28328
AKOS024457607
CS-5738
HY-13428
CHEBI:94166
Z2235802242
tubacin, >=98% (hplc)
NCGC00346840-03
tubacin (bml-gr362)
SW219084-1
EX-A2172
Q27089032
CCG-270408
rel-n1-(4-((2r,4r,6s)-4-(((4,5-diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-n8-hydroxyoctanediamide
n1-(4-((2r,4r,6s)-4-((4,5-diphenyloxazol-2-ylthio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-n8-hydroxyoctanediamide

Excerpt	Reference	Relevance
"Tubacin is a small molecule inhibitor of HDAC6 selected for its selective inhibition of HDAC6 relative to other histone deacetylases."	( The histone deacetylase-6 inhibitor tubacin directly inhibits de novo sphingolipid biosynthesis as an off-target effect. Siow, D; Wattenberg, B, 2014)	1.4
"Tubacin is a domain-specific inhibitor and binds to one of the two HDAC6 catalytic domains possessing tubulin deacetylase activity."	( Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules. Cheung, CY; Husain, M, 2014)	1.12
"Tubacin is a small molecule inhibitor of histone deacetylase 6 and blocks aggresome activity. "	( Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. Bradner, JE; Cohen, JI; Kawada, J; Mazitschek, R; Zou, P, 2009)	3.24

Excerpt	Reference	Relevance
"Tubacin treatment did not affect the stability of microtubules but did decrease cell motility."	( Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Grozinger, CM; Haggarty, SJ; Koeller, KM; Schreiber, SL; Wong, JC, 2003)	1.04
"Treatment with tubacin prevented cyst formation in MDCK cells, an in vitro model of cystogenesis."	( Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease. Boinot, C; Cebotaru, L; Cebotaru, V; Guggino, WB; Huso, DL; Liu, Q; Outeda, P; Watnick, T; Yanda, MK, 2016)	0.77
"Treatment with tubacin, a selective inhibitor of tubulin deacetylation activity of HDAC6, did not disrupt HDAC6-tau interaction."	( Histone deacetylase 6 interacts with the microtubule-associated protein tau. Ding, H; Dolan, PJ; Johnson, GV, 2008)	0.69
"Treatment with tubacin led to the induction of apoptotic pathways in both pre-B and T cell ALL cells at a 50% inhibitory concentration (IC(50)) of low micromolar concentrations."	( Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Aldana-Masangkay, GI; Bradner, JE; Hsieh, YT; Ikeda, AK; Kim, YM; Landaw, EM; Lin, T; Lomenick, B; Mazitschek, R; Okemoto, K; Rodriguez-Gonzalez, A; Sakamoto, KM; Wang, D, 2011)	2.15

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
1,3-oxazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	9.6314	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histone deacetylase 3	Homo sapiens (human)	IC50 (µMol)	1.1900	0.0004	0.6196	10.0000	AID1173501; AID1384208; AID1525779; AID1783134; AID1882466; AID488275; AID767952; AID772637
Histone deacetylase 3	Homo sapiens (human)	Ki	0.4097	0.0002	0.4237	8.1900	AID1236444; AID496803
Leukotriene A-4 hydrolase	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0005	1.2854	7.6500	AID1441630; AID1441631
Histone deacetylase 4	Homo sapiens (human)	IC50 (µMol)	17.3000	0.0006	1.0526	10.0000	AID1173502; AID1783135; AID767951; AID772636
Histone deacetylase 4	Homo sapiens (human)	Ki	13.0621	0.0002	1.6255	9.1242	AID1236446; AID496804
Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)	IC50 (µMol)	4.5725	0.0200	2.6609	9.4300	AID1677972; AID1677973; AID1677974; AID1677975
Histone deacetylase 1	Homo sapiens (human)	IC50 (µMol)	1.2450	0.0001	0.5543	9.9000	AID1173499; AID1384206; AID1525777; AID1572341; AID1572374; AID1783132; AID1882456; AID488273; AID767954; AID772654
Histone deacetylase 1	Homo sapiens (human)	Ki	1.4644	0.0000	0.4988	8.1900	AID1236442; AID1798196; AID385229; AID496801
Histone deacetylase 7	Homo sapiens (human)	IC50 (µMol)	9.7000	0.0007	1.0260	9.9000	AID1173504; AID1783138; AID767948; AID772633
Histone deacetylase 7	Homo sapiens (human)	Ki	6.9634	0.0002	2.0005	9.5000	AID1236448; AID496807
Histone deacetylase 2	Homo sapiens (human)	IC50 (µMol)	5.5187	0.0001	0.7221	9.9700	AID1173500; AID1384207; AID1525778; AID1783133; AID1882457; AID488274; AID767953; AID772638
Histone deacetylase 2	Homo sapiens (human)	Ki	0.6113	0.0000	0.4709	8.1900	AID1236443; AID496802
HD2 type histone deacetylase HDA106	Zea mays	IC50 (µMol)	2.0000	0.0030	0.1737	2.0000	AID241474
Polyamine deacetylase HDAC10	Homo sapiens (human)	IC50 (µMol)	3.7100	0.0005	0.7245	9.9000	AID1173506; AID1783141; AID767945; AID772630
Polyamine deacetylase HDAC10	Homo sapiens (human)	Ki	0.3737	0.0000	0.7687	8.1900	AID1236451
Histone deacetylase 11	Homo sapiens (human)	IC50 (µMol)	3.7900	0.0003	0.9298	9.9000	AID1173507; AID1783142; AID767944; AID772631
Histone deacetylase 11	Homo sapiens (human)	Ki	0.7187	0.0001	1.2147	8.1900	AID1236452
Histone deacetylase 8	Homo sapiens (human)	IC50 (µMol)	1.8029	0.0007	0.9947	9.9000	AID1173505; AID1525780; AID1783139; AID1882467; AID488277; AID767947; AID772632
Histone deacetylase 8	Homo sapiens (human)	Ki	1.5500	0.0002	0.7525	8.1900	AID1236445; AID1798196; AID496808
Histone deacetylase 6	Homo sapiens (human)	IC50 (µMol)	0.4668	0.0000	0.5376	9.9000	AID1173495; AID1173497; AID1384209; AID1525776; AID1532657; AID1572342; AID1572375; AID1731764; AID1783137; AID1819859; AID1882462; AID1895827; AID488276; AID767949; AID772635; AID772650
Histone deacetylase 6	Homo sapiens (human)	Ki	1.2660	0.0001	0.4156	8.1900	AID1236450; AID1798196; AID385230; AID496806
Histone deacetylase 9	Homo sapiens (human)	IC50 (µMol)	4.3100	0.0005	0.9413	9.9000	AID1783140; AID767946
Histone deacetylase 9	Homo sapiens (human)	Ki	3.4047	0.0002	1.8520	9.0000	AID1236449; AID385231
Histone deacetylase 5	Homo sapiens (human)	IC50 (µMol)	3.3500	0.0007	0.9610	10.0000	AID1173503; AID1783136; AID767950; AID772634
Histone deacetylase 5	Homo sapiens (human)	Ki	1.7098	0.0002	1.2993	9.5000	AID1236447; AID496805
Nuclear receptor corepressor 2	Homo sapiens (human)	IC50 (µMol)	1.2700	0.0017	0.5952	8.0000	AID767952; AID772637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histone deacetylase 1	Homo sapiens (human)	EC50 (µMol)	217.0000	0.0300	1.9877	6.7000	AID90679
Histone deacetylase 6	Homo sapiens (human)	EC50 (µMol)	2.9000	0.0052	1.5998	6.7000	AID512609; AID90836
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of myotube differentiation	Histone deacetylase 3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
establishment of mitotic spindle orientation	Histone deacetylase 3	Homo sapiens (human)
in utero embryonic development	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein phosphorylation	Histone deacetylase 3	Homo sapiens (human)
chromatin organization	Histone deacetylase 3	Homo sapiens (human)
transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
protein deacetylation	Histone deacetylase 3	Homo sapiens (human)
regulation of mitotic cell cycle	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein ubiquitination	Histone deacetylase 3	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 3	Homo sapiens (human)
positive regulation of TOR signaling	Histone deacetylase 3	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 3	Homo sapiens (human)
regulation of multicellular organism growth	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein import into nucleus	Histone deacetylase 3	Homo sapiens (human)
regulation of circadian rhythm	Histone deacetylase 3	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 3	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
negative regulation of JNK cascade	Histone deacetylase 3	Homo sapiens (human)
spindle assembly	Histone deacetylase 3	Homo sapiens (human)
establishment of skin barrier	Histone deacetylase 3	Homo sapiens (human)
cellular response to fluid shear stress	Histone deacetylase 3	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Histone deacetylase 3	Homo sapiens (human)
DNA repair-dependent chromatin remodeling	Histone deacetylase 3	Homo sapiens (human)
cornified envelope assembly	Histone deacetylase 3	Homo sapiens (human)
negative regulation of cardiac muscle cell differentiation	Histone deacetylase 3	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 3	Homo sapiens (human)
proteolysis	Leukotriene A-4 hydrolase	Homo sapiens (human)
lipid metabolic process	Leukotriene A-4 hydrolase	Homo sapiens (human)
response to zinc ion	Leukotriene A-4 hydrolase	Homo sapiens (human)
leukotriene biosynthetic process	Leukotriene A-4 hydrolase	Homo sapiens (human)
protein metabolic process	Leukotriene A-4 hydrolase	Homo sapiens (human)
peptide catabolic process	Leukotriene A-4 hydrolase	Homo sapiens (human)
response to peptide hormone	Leukotriene A-4 hydrolase	Homo sapiens (human)
type I pneumocyte differentiation	Leukotriene A-4 hydrolase	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 4	Homo sapiens (human)
protein deacetylation	Histone deacetylase 4	Homo sapiens (human)
inflammatory response	Histone deacetylase 4	Homo sapiens (human)
nervous system development	Histone deacetylase 4	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 4	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 4	Homo sapiens (human)
negative regulation of transcription by competitive promoter binding	Histone deacetylase 4	Homo sapiens (human)
response to denervation involved in regulation of muscle adaptation	Histone deacetylase 4	Homo sapiens (human)
cardiac muscle hypertrophy in response to stress	Histone deacetylase 4	Homo sapiens (human)
protein sumoylation	Histone deacetylase 4	Homo sapiens (human)
B cell differentiation	Histone deacetylase 4	Homo sapiens (human)
positive regulation of protein sumoylation	Histone deacetylase 4	Homo sapiens (human)
peptidyl-lysine deacetylation	Histone deacetylase 4	Homo sapiens (human)
B cell activation	Histone deacetylase 4	Homo sapiens (human)
regulation of protein binding	Histone deacetylase 4	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Histone deacetylase 4	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 4	Homo sapiens (human)
negative regulation of glycolytic process	Histone deacetylase 4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Histone deacetylase 4	Homo sapiens (human)
type I interferon-mediated signaling pathway	Histone deacetylase 4	Homo sapiens (human)
response to interleukin-1	Histone deacetylase 4	Homo sapiens (human)
muscle contraction	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
pattern specification process	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
cell population proliferation	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
negative regulation of cell population proliferation	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
regulation of protein stability	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
limb morphogenesis	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
positive regulation of proteolysis	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
roof of mouth development	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
face morphogenesis	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
activation of cysteine-type endopeptidase activity	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
regulation of protein depolymerization	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
peptidyl-aspartic acid hydroxylation	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
chromatin organization	Histone deacetylase 1	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
protein deacetylation	Histone deacetylase 1	Homo sapiens (human)
endoderm development	Histone deacetylase 1	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 1	Homo sapiens (human)
epidermal cell differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
hippocampus development	Histone deacetylase 1	Homo sapiens (human)
neuron differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of cell migration	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Histone deacetylase 1	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Histone deacetylase 1	Homo sapiens (human)
regulation of cell fate specification	Histone deacetylase 1	Homo sapiens (human)
embryonic digit morphogenesis	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Histone deacetylase 1	Homo sapiens (human)
negative regulation by host of viral transcription	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Histone deacetylase 1	Homo sapiens (human)
oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
hair follicle placode formation	Histone deacetylase 1	Homo sapiens (human)
eyelid development in camera-type eye	Histone deacetylase 1	Homo sapiens (human)
fungiform papilla formation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Histone deacetylase 1	Homo sapiens (human)
negative regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
positive regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
regulation of stem cell differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Histone deacetylase 1	Homo sapiens (human)
heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 7	Homo sapiens (human)
vasculogenesis	Histone deacetylase 7	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 7	Homo sapiens (human)
protein deacetylation	Histone deacetylase 7	Homo sapiens (human)
cell-cell junction assembly	Histone deacetylase 7	Homo sapiens (human)
protein sumoylation	Histone deacetylase 7	Homo sapiens (human)
negative regulation of interleukin-2 production	Histone deacetylase 7	Homo sapiens (human)
negative regulation of osteoblast differentiation	Histone deacetylase 7	Homo sapiens (human)
regulation of mRNA processing	Histone deacetylase 7	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Histone deacetylase 7	Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transduction	Histone deacetylase 7	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 2	Homo sapiens (human)
response to amphetamine	Histone deacetylase 2	Homo sapiens (human)
cardiac muscle hypertrophy	Histone deacetylase 2	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 2	Homo sapiens (human)
response to xenobiotic stimulus	Histone deacetylase 2	Homo sapiens (human)
epidermal cell differentiation	Histone deacetylase 2	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by competitive promoter binding	Histone deacetylase 2	Homo sapiens (human)
negative regulation of neuron projection development	Histone deacetylase 2	Homo sapiens (human)
dendrite development	Histone deacetylase 2	Homo sapiens (human)
negative regulation of cell migration	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Histone deacetylase 2	Homo sapiens (human)
response to caffeine	Histone deacetylase 2	Homo sapiens (human)
heterochromatin formation	Histone deacetylase 2	Homo sapiens (human)
response to lipopolysaccharide	Histone deacetylase 2	Homo sapiens (human)
positive regulation of interleukin-1 production	Histone deacetylase 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Histone deacetylase 2	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 2	Homo sapiens (human)
positive regulation of collagen biosynthetic process	Histone deacetylase 2	Homo sapiens (human)
cellular response to heat	Histone deacetylase 2	Homo sapiens (human)
response to nicotine	Histone deacetylase 2	Homo sapiens (human)
protein modification process	Histone deacetylase 2	Homo sapiens (human)
response to cocaine	Histone deacetylase 2	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Histone deacetylase 2	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Histone deacetylase 2	Homo sapiens (human)
regulation of cell fate specification	Histone deacetylase 2	Homo sapiens (human)
embryonic digit morphogenesis	Histone deacetylase 2	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 2	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Histone deacetylase 2	Homo sapiens (human)
negative regulation of MHC class II biosynthetic process	Histone deacetylase 2	Homo sapiens (human)
positive regulation of proteolysis	Histone deacetylase 2	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 2	Homo sapiens (human)
behavioral response to ethanol	Histone deacetylase 2	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Histone deacetylase 2	Homo sapiens (human)
response to hyperoxia	Histone deacetylase 2	Homo sapiens (human)
hair follicle placode formation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of dendritic spine development	Histone deacetylase 2	Homo sapiens (human)
eyelid development in camera-type eye	Histone deacetylase 2	Homo sapiens (human)
fungiform papilla formation	Histone deacetylase 2	Homo sapiens (human)
cellular response to hydrogen peroxide	Histone deacetylase 2	Homo sapiens (human)
cellular response to retinoic acid	Histone deacetylase 2	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Histone deacetylase 2	Homo sapiens (human)
positive regulation of male mating behavior	Histone deacetylase 2	Homo sapiens (human)
negative regulation of stem cell population maintenance	Histone deacetylase 2	Homo sapiens (human)
positive regulation of stem cell population maintenance	Histone deacetylase 2	Homo sapiens (human)
cellular response to dopamine	Histone deacetylase 2	Homo sapiens (human)
response to amyloid-beta	Histone deacetylase 2	Homo sapiens (human)
regulation of stem cell differentiation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of peptidyl-lysine acetylation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Polyamine deacetylase HDAC10	Homo sapiens (human)
DNA repair	Polyamine deacetylase HDAC10	Homo sapiens (human)
chromatin organization	Polyamine deacetylase HDAC10	Homo sapiens (human)
regulation of DNA-templated transcription	Polyamine deacetylase HDAC10	Homo sapiens (human)
macroautophagy	Polyamine deacetylase HDAC10	Homo sapiens (human)
positive regulation of mismatch repair	Polyamine deacetylase HDAC10	Homo sapiens (human)
homologous recombination	Polyamine deacetylase HDAC10	Homo sapiens (human)
negative regulation of DNA-templated transcription	Polyamine deacetylase HDAC10	Homo sapiens (human)
polyamine deacetylation	Polyamine deacetylase HDAC10	Homo sapiens (human)
spermidine deacetylation	Polyamine deacetylase HDAC10	Homo sapiens (human)
epigenetic regulation of gene expression	Polyamine deacetylase HDAC10	Homo sapiens (human)
chromatin organization	Histone deacetylase 11	Homo sapiens (human)
oligodendrocyte development	Histone deacetylase 11	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 11	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 8	Homo sapiens (human)
chromatin organization	Histone deacetylase 8	Homo sapiens (human)
mitotic sister chromatid cohesion	Histone deacetylase 8	Homo sapiens (human)
negative regulation of protein ubiquitination	Histone deacetylase 8	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 8	Homo sapiens (human)
regulation of telomere maintenance	Histone deacetylase 8	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 8	Homo sapiens (human)
polyamine deacetylation	Histone deacetylase 6	Homo sapiens (human)
spermidine deacetylation	Histone deacetylase 6	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 6	Homo sapiens (human)
protein polyubiquitination	Histone deacetylase 6	Homo sapiens (human)
response to amphetamine	Histone deacetylase 6	Homo sapiens (human)
protein deacetylation	Histone deacetylase 6	Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteins	Histone deacetylase 6	Homo sapiens (human)
intracellular protein transport	Histone deacetylase 6	Homo sapiens (human)
autophagy	Histone deacetylase 6	Homo sapiens (human)
actin filament organization	Histone deacetylase 6	Homo sapiens (human)
negative regulation of microtubule depolymerization	Histone deacetylase 6	Homo sapiens (human)
regulation of autophagy	Histone deacetylase 6	Homo sapiens (human)
positive regulation of epithelial cell migration	Histone deacetylase 6	Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic process	Histone deacetylase 6	Homo sapiens (human)
regulation of macroautophagy	Histone deacetylase 6	Homo sapiens (human)
axonal transport of mitochondrion	Histone deacetylase 6	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Histone deacetylase 6	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 6	Homo sapiens (human)
protein destabilization	Histone deacetylase 6	Homo sapiens (human)
lysosome localization	Histone deacetylase 6	Homo sapiens (human)
protein-containing complex disassembly	Histone deacetylase 6	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Histone deacetylase 6	Homo sapiens (human)
cellular response to heat	Histone deacetylase 6	Homo sapiens (human)
peptidyl-lysine deacetylation	Histone deacetylase 6	Homo sapiens (human)
response to immobilization stress	Histone deacetylase 6	Homo sapiens (human)
cellular response to topologically incorrect protein	Histone deacetylase 6	Homo sapiens (human)
erythrocyte enucleation	Histone deacetylase 6	Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway	Histone deacetylase 6	Homo sapiens (human)
negative regulation of protein-containing complex disassembly	Histone deacetylase 6	Homo sapiens (human)
regulation of fat cell differentiation	Histone deacetylase 6	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 6	Homo sapiens (human)
negative regulation of proteolysis	Histone deacetylase 6	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 6	Homo sapiens (human)
collateral sprouting	Histone deacetylase 6	Homo sapiens (human)
negative regulation of axon extension involved in axon guidance	Histone deacetylase 6	Homo sapiens (human)
positive regulation of dendrite morphogenesis	Histone deacetylase 6	Homo sapiens (human)
negative regulation of oxidoreductase activity	Histone deacetylase 6	Homo sapiens (human)
response to corticosterone	Histone deacetylase 6	Homo sapiens (human)
response to misfolded protein	Histone deacetylase 6	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Histone deacetylase 6	Homo sapiens (human)
cilium assembly	Histone deacetylase 6	Homo sapiens (human)
regulation of microtubule-based movement	Histone deacetylase 6	Homo sapiens (human)
regulation of androgen receptor signaling pathway	Histone deacetylase 6	Homo sapiens (human)
dendritic spine morphogenesis	Histone deacetylase 6	Homo sapiens (human)
cilium disassembly	Histone deacetylase 6	Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization	Histone deacetylase 6	Homo sapiens (human)
regulation of establishment of protein localization	Histone deacetylase 6	Homo sapiens (human)
cellular response to hydrogen peroxide	Histone deacetylase 6	Homo sapiens (human)
aggresome assembly	Histone deacetylase 6	Homo sapiens (human)
polyubiquitinated misfolded protein transport	Histone deacetylase 6	Homo sapiens (human)
response to growth factor	Histone deacetylase 6	Homo sapiens (human)
cellular response to misfolded protein	Histone deacetylase 6	Homo sapiens (human)
cellular response to parathyroid hormone stimulus	Histone deacetylase 6	Homo sapiens (human)
response to dexamethasone	Histone deacetylase 6	Homo sapiens (human)
tubulin deacetylation	Histone deacetylase 6	Homo sapiens (human)
positive regulation of tubulin deacetylation	Histone deacetylase 6	Homo sapiens (human)
positive regulation of cellular response to oxidative stress	Histone deacetylase 6	Homo sapiens (human)
negative regulation of protein acetylation	Histone deacetylase 6	Homo sapiens (human)
regulation of autophagy of mitochondrion	Histone deacetylase 6	Homo sapiens (human)
positive regulation of cholangiocyte proliferation	Histone deacetylase 6	Homo sapiens (human)
negative regulation of aggrephagy	Histone deacetylase 6	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 6	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 9	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 9	Homo sapiens (human)
negative regulation of cytokine production	Histone deacetylase 9	Homo sapiens (human)
response to amphetamine	Histone deacetylase 9	Homo sapiens (human)
inflammatory response	Histone deacetylase 9	Homo sapiens (human)
heart development	Histone deacetylase 9	Homo sapiens (human)
neuron differentiation	Histone deacetylase 9	Homo sapiens (human)
B cell differentiation	Histone deacetylase 9	Homo sapiens (human)
cellular response to insulin stimulus	Histone deacetylase 9	Homo sapiens (human)
peptidyl-lysine deacetylation	Histone deacetylase 9	Homo sapiens (human)
B cell activation	Histone deacetylase 9	Homo sapiens (human)
cholesterol homeostasis	Histone deacetylase 9	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 9	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 9	Homo sapiens (human)
regulation of skeletal muscle fiber development	Histone deacetylase 9	Homo sapiens (human)
regulation of striated muscle cell differentiation	Histone deacetylase 9	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Histone deacetylase 9	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 5	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 5	Homo sapiens (human)
inflammatory response	Histone deacetylase 5	Homo sapiens (human)
response to xenobiotic stimulus	Histone deacetylase 5	Homo sapiens (human)
regulation of myotube differentiation	Histone deacetylase 5	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 5	Homo sapiens (human)
response to activity	Histone deacetylase 5	Homo sapiens (human)
neuron differentiation	Histone deacetylase 5	Homo sapiens (human)
B cell differentiation	Histone deacetylase 5	Homo sapiens (human)
cellular response to insulin stimulus	Histone deacetylase 5	Homo sapiens (human)
B cell activation	Histone deacetylase 5	Homo sapiens (human)
response to cocaine	Histone deacetylase 5	Homo sapiens (human)
regulation of protein binding	Histone deacetylase 5	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 5	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 5	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 5	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Histone deacetylase 5	Homo sapiens (human)
cellular response to lipopolysaccharide	Histone deacetylase 5	Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesis	Histone deacetylase 5	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor corepressor 2	Homo sapiens (human)
lactation	Nuclear receptor corepressor 2	Homo sapiens (human)
response to organonitrogen compound	Nuclear receptor corepressor 2	Homo sapiens (human)
regulation of cellular ketone metabolic process	Nuclear receptor corepressor 2	Homo sapiens (human)
cerebellum development	Nuclear receptor corepressor 2	Homo sapiens (human)
response to estradiol	Nuclear receptor corepressor 2	Homo sapiens (human)
estrous cycle	Nuclear receptor corepressor 2	Homo sapiens (human)
negative regulation of DNA-templated transcription	Nuclear receptor corepressor 2	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	Nuclear receptor corepressor 2	Homo sapiens (human)
negative regulation of miRNA transcription	Nuclear receptor corepressor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription corepressor binding	Histone deacetylase 3	Homo sapiens (human)
chromatin binding	Histone deacetylase 3	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 3	Homo sapiens (human)
protein binding	Histone deacetylase 3	Homo sapiens (human)
enzyme binding	Histone deacetylase 3	Homo sapiens (human)
cyclin binding	Histone deacetylase 3	Homo sapiens (human)
chromatin DNA binding	Histone deacetylase 3	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 3	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 3	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 3	Homo sapiens (human)
protein decrotonylase activity	Histone deacetylase 3	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 3	Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activity	Histone deacetylase 3	Homo sapiens (human)
RNA binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
aminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
epoxide hydrolase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
leukotriene-A4 hydrolase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
protein binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
peptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
zinc ion binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
tripeptide aminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
metalloaminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
transcription cis-regulatory region binding	Histone deacetylase 4	Homo sapiens (human)
histone binding	Histone deacetylase 4	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 4	Homo sapiens (human)
protein binding	Histone deacetylase 4	Homo sapiens (human)
zinc ion binding	Histone deacetylase 4	Homo sapiens (human)
SUMO transferase activity	Histone deacetylase 4	Homo sapiens (human)
potassium ion binding	Histone deacetylase 4	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 4	Homo sapiens (human)
identical protein binding	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 4	Homo sapiens (human)
molecular adaptor activity	Histone deacetylase 4	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 4	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 4	Homo sapiens (human)
structural molecule activity	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
calcium ion binding	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
protein binding	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
structural constituent of muscle	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
electron transfer activity	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
peptidyl-aspartic acid 3-dioxygenase activity	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
nucleosomal DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 1	Homo sapiens (human)
p53 binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
protein binding	Histone deacetylase 1	Homo sapiens (human)
enzyme binding	Histone deacetylase 1	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
Krueppel-associated box domain binding	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 1	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
E-box binding	Histone deacetylase 1	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 1	Homo sapiens (human)
promoter-specific chromatin binding	Histone deacetylase 1	Homo sapiens (human)
chromatin binding	Histone deacetylase 7	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 7	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 7	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 7	Homo sapiens (human)
protein binding	Histone deacetylase 7	Homo sapiens (human)
SUMO transferase activity	Histone deacetylase 7	Homo sapiens (human)
protein kinase binding	Histone deacetylase 7	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 7	Homo sapiens (human)
metal ion binding	Histone deacetylase 7	Homo sapiens (human)
14-3-3 protein binding	Histone deacetylase 7	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 7	Homo sapiens (human)
nucleosomal DNA binding	Histone deacetylase 2	Homo sapiens (human)
chromatin binding	Histone deacetylase 2	Homo sapiens (human)
RNA binding	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 2	Homo sapiens (human)
protein binding	Histone deacetylase 2	Homo sapiens (human)
enzyme binding	Histone deacetylase 2	Homo sapiens (human)
heat shock protein binding	Histone deacetylase 2	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 2	Homo sapiens (human)
histone binding	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 2	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 2	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 2	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 2	Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activity	Histone deacetylase 2	Homo sapiens (human)
promoter-specific chromatin binding	Histone deacetylase 2	Homo sapiens (human)
protein lysine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
protein binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
zinc ion binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
enzyme binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
protein lysine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
acetylputrescine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
acetylspermidine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 11	Homo sapiens (human)
protein binding	Histone deacetylase 11	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 11	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 8	Homo sapiens (human)
protein binding	Histone deacetylase 8	Homo sapiens (human)
Hsp70 protein binding	Histone deacetylase 8	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 8	Homo sapiens (human)
metal ion binding	Histone deacetylase 8	Homo sapiens (human)
Hsp90 protein binding	Histone deacetylase 8	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 8	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 8	Homo sapiens (human)
acetylspermidine deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 6	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 6	Homo sapiens (human)
actin binding	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
protein binding	Histone deacetylase 6	Homo sapiens (human)
beta-catenin binding	Histone deacetylase 6	Homo sapiens (human)
microtubule binding	Histone deacetylase 6	Homo sapiens (human)
zinc ion binding	Histone deacetylase 6	Homo sapiens (human)
enzyme binding	Histone deacetylase 6	Homo sapiens (human)
polyubiquitin modification-dependent protein binding	Histone deacetylase 6	Homo sapiens (human)
ubiquitin protein ligase binding	Histone deacetylase 6	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 6	Homo sapiens (human)
tubulin deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
alpha-tubulin binding	Histone deacetylase 6	Homo sapiens (human)
ubiquitin binding	Histone deacetylase 6	Homo sapiens (human)
tau protein binding	Histone deacetylase 6	Homo sapiens (human)
beta-tubulin binding	Histone deacetylase 6	Homo sapiens (human)
misfolded protein binding	Histone deacetylase 6	Homo sapiens (human)
Hsp90 protein binding	Histone deacetylase 6	Homo sapiens (human)
dynein complex binding	Histone deacetylase 6	Homo sapiens (human)
transcription factor binding	Histone deacetylase 6	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 9	Homo sapiens (human)
protein binding	Histone deacetylase 9	Homo sapiens (human)
histone H3K14 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone H3K9 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone H4K16 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 9	Homo sapiens (human)
metal ion binding	Histone deacetylase 9	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 9	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 9	Homo sapiens (human)
transcription cis-regulatory region binding	Histone deacetylase 5	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 5	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 5	Homo sapiens (human)
chromatin binding	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 5	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 5	Homo sapiens (human)
protein binding	Histone deacetylase 5	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 5	Homo sapiens (human)
identical protein binding	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 5	Homo sapiens (human)
metal ion binding	Histone deacetylase 5	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 5	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 5	Homo sapiens (human)
DNA binding	Nuclear receptor corepressor 2	Homo sapiens (human)
chromatin binding	Nuclear receptor corepressor 2	Homo sapiens (human)
transcription corepressor activity	Nuclear receptor corepressor 2	Homo sapiens (human)
Notch binding	Nuclear receptor corepressor 2	Homo sapiens (human)
protein binding	Nuclear receptor corepressor 2	Homo sapiens (human)
nuclear glucocorticoid receptor binding	Nuclear receptor corepressor 2	Homo sapiens (human)
histone deacetylase binding	Nuclear receptor corepressor 2	Homo sapiens (human)
nuclear retinoid X receptor binding	Nuclear receptor corepressor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Histone deacetylase 3	Homo sapiens (human)
nucleoplasm	Histone deacetylase 3	Homo sapiens (human)
cytoplasm	Histone deacetylase 3	Homo sapiens (human)
Golgi apparatus	Histone deacetylase 3	Homo sapiens (human)
cytosol	Histone deacetylase 3	Homo sapiens (human)
plasma membrane	Histone deacetylase 3	Homo sapiens (human)
mitotic spindle	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 3	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 3	Homo sapiens (human)
nucleus	Histone deacetylase 3	Homo sapiens (human)
extracellular region	Leukotriene A-4 hydrolase	Homo sapiens (human)
nucleoplasm	Leukotriene A-4 hydrolase	Homo sapiens (human)
cytosol	Leukotriene A-4 hydrolase	Homo sapiens (human)
extracellular exosome	Leukotriene A-4 hydrolase	Homo sapiens (human)
tertiary granule lumen	Leukotriene A-4 hydrolase	Homo sapiens (human)
ficolin-1-rich granule lumen	Leukotriene A-4 hydrolase	Homo sapiens (human)
cytosol	Leukotriene A-4 hydrolase	Homo sapiens (human)
nucleus	Leukotriene A-4 hydrolase	Homo sapiens (human)
nucleus	Histone deacetylase 4	Homo sapiens (human)
nucleoplasm	Histone deacetylase 4	Homo sapiens (human)
cytoplasm	Histone deacetylase 4	Homo sapiens (human)
cytosol	Histone deacetylase 4	Homo sapiens (human)
nuclear speck	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 4	Homo sapiens (human)
chromatin	Histone deacetylase 4	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 4	Homo sapiens (human)
endoplasmic reticulum	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
endoplasmic reticulum membrane	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
plasma membrane	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
cortical endoplasmic reticulum	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
sarcoplasmic reticulum membrane	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
endoplasmic reticulum	Aspartyl/asparaginyl beta-hydroxylase	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleoplasm	Histone deacetylase 1	Homo sapiens (human)
cytoplasm	Histone deacetylase 1	Homo sapiens (human)
cytosol	Histone deacetylase 1	Homo sapiens (human)
NuRD complex	Histone deacetylase 1	Homo sapiens (human)
neuronal cell body	Histone deacetylase 1	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 1	Homo sapiens (human)
chromatin	Histone deacetylase 1	Homo sapiens (human)
heterochromatin	Histone deacetylase 1	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 1	Homo sapiens (human)
protein-containing complex	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 7	Homo sapiens (human)
nucleoplasm	Histone deacetylase 7	Homo sapiens (human)
cytoplasm	Histone deacetylase 7	Homo sapiens (human)
cytosol	Histone deacetylase 7	Homo sapiens (human)
chromosome, telomeric region	Histone deacetylase 2	Homo sapiens (human)
nucleus	Histone deacetylase 2	Homo sapiens (human)
nucleoplasm	Histone deacetylase 2	Homo sapiens (human)
cytoplasm	Histone deacetylase 2	Homo sapiens (human)
NuRD complex	Histone deacetylase 2	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 2	Homo sapiens (human)
chromatin	Histone deacetylase 2	Homo sapiens (human)
protein-containing complex	Histone deacetylase 2	Homo sapiens (human)
ESC/E(Z) complex	Histone deacetylase 2	Homo sapiens (human)
nucleus	Histone deacetylase 2	Homo sapiens (human)
nucleus	Polyamine deacetylase HDAC10	Homo sapiens (human)
nucleoplasm	Polyamine deacetylase HDAC10	Homo sapiens (human)
cytoplasm	Polyamine deacetylase HDAC10	Homo sapiens (human)
cytosol	Polyamine deacetylase HDAC10	Homo sapiens (human)
intracellular membrane-bounded organelle	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase complex	Polyamine deacetylase HDAC10	Homo sapiens (human)
nucleus	Histone deacetylase 11	Homo sapiens (human)
plasma membrane	Histone deacetylase 11	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 11	Homo sapiens (human)
nuclear chromosome	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 8	Homo sapiens (human)
nucleoplasm	Histone deacetylase 8	Homo sapiens (human)
cytoplasm	Histone deacetylase 8	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 6	Homo sapiens (human)
nucleoplasm	Histone deacetylase 6	Homo sapiens (human)
cytoplasm	Histone deacetylase 6	Homo sapiens (human)
multivesicular body	Histone deacetylase 6	Homo sapiens (human)
centrosome	Histone deacetylase 6	Homo sapiens (human)
cytosol	Histone deacetylase 6	Homo sapiens (human)
microtubule	Histone deacetylase 6	Homo sapiens (human)
caveola	Histone deacetylase 6	Homo sapiens (human)
inclusion body	Histone deacetylase 6	Homo sapiens (human)
aggresome	Histone deacetylase 6	Homo sapiens (human)
axon	Histone deacetylase 6	Homo sapiens (human)
dendrite	Histone deacetylase 6	Homo sapiens (human)
cell leading edge	Histone deacetylase 6	Homo sapiens (human)
ciliary basal body	Histone deacetylase 6	Homo sapiens (human)
perikaryon	Histone deacetylase 6	Homo sapiens (human)
perinuclear region of cytoplasm	Histone deacetylase 6	Homo sapiens (human)
axon cytoplasm	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 6	Homo sapiens (human)
microtubule associated complex	Histone deacetylase 6	Homo sapiens (human)
nucleus	Histone deacetylase 9	Homo sapiens (human)
nucleoplasm	Histone deacetylase 9	Homo sapiens (human)
cytoplasm	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 9	Homo sapiens (human)
transcription regulator complex	Histone deacetylase 9	Homo sapiens (human)
histone methyltransferase complex	Histone deacetylase 9	Homo sapiens (human)
nucleus	Histone deacetylase 5	Homo sapiens (human)
nucleoplasm	Histone deacetylase 5	Homo sapiens (human)
cytoplasm	Histone deacetylase 5	Homo sapiens (human)
Golgi apparatus	Histone deacetylase 5	Homo sapiens (human)
cytosol	Histone deacetylase 5	Homo sapiens (human)
nuclear speck	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 5	Homo sapiens (human)
nucleus	Nuclear receptor corepressor 2	Homo sapiens (human)
nucleoplasm	Nuclear receptor corepressor 2	Homo sapiens (human)
membrane	Nuclear receptor corepressor 2	Homo sapiens (human)
nuclear matrix	Nuclear receptor corepressor 2	Homo sapiens (human)
nuclear body	Nuclear receptor corepressor 2	Homo sapiens (human)
chromatin	Nuclear receptor corepressor 2	Homo sapiens (human)
transcription repressor complex	Nuclear receptor corepressor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (163)

Assay ID	Title	Year	Journal	Article
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1572375	Inhibition of recombinant human HDAC6 using RHKKAc fluorogenic peptide substrate	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1173501	Inhibition of full length C-terminal 6x-His tagged human HDAC3 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1525780	Inhibition of HADC8 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID496807	Inhibition of human HDAC7	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID772633	Inhibition of human recombinant HDAC7 using acetyl-Lys(trifluoroacetyl)-AMC as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID1173505	Inhibition of full length C-terminal 6x-His tagged human HDAC8 using Arg-His-Lys(Ac)-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1731765	Inhibition of recombinant human HDAC8 using Ac-LGK(TFA)-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 90 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1677971	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) at 20uM using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID385230	Inhibition of HDAC6	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
AID1173507	Inhibition of full length N-terminal GST-tagged human HDAC11 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID772631	Inhibition of human recombinant HDAC11 using RHKKAc as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID1173497	Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID767945	Inhibition of human recombinant HDAC10 protein using RHKKAc from p53 as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID241474	Inhibitory concentration against maize histone deacetylase 2	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID767952	Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc from p53 as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1572374	Inhibition of recombinant human HDAC1 using RHKKAc fluorogenic peptide substrate	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID767949	Inhibition of human recombinant HDAC6 protein using RHKKAc from p53 as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID488275	Inhibition of HDAC3	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID488274	Inhibition of HDAC2	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID767948	Inhibition of human recombinant HDAC7 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID764211	Selectivity ratio of IC50 for human recombinant HDAC1 to human recombinant HDAC6	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID496801	Inhibition of human HDAC1	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1236445	Inhibition of human HDAC8	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1173506	Inhibition of N-terminal GST-tagged human HDAC10 (1 to 481 residues) using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1677975	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using high 10 uM hFX-CP as substrate mixture with 10 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1783136	Inhibition of HDAC5 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID772630	Inhibition of human recombinant HDAC10 using RHKKAc as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID90836	Tested for inhibition of Histone deacetylase 6 induced acetylated tubulin in mammalian cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1895827	Inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
AID1236441	Antitrypanosomal activity against Trypanosoma brucei brucei 427 assessed as inhibition of parasite proliferation measured as ATP levels after 48 hrs by luciferase-based assay	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1441630	Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA preincubated for 10 mins followed by substrate addition measured after 10 mins	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1572342	Inhibition of recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID767950	Inhibition of human recombinant HDAC5 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID496802	Inhibition of human HDAC2	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID772636	Inhibition of human recombinant HDAC4 using acetyl-Lys(trifluoroacetyl)-AMC as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID1532657	Inhibition of human HDAC6 using (Z-(Ac)Lys-AMC) as substrate after 90 mins by fluorescence analysis	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Highly fluorescent and HDAC6 selective scriptaid analogues.
AID488273	Inhibition of HDAC1	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID1173495	Inhibition of recombinant N-GST-tagged HDAC6 (unknown origin) assessed as reduction in deacetylation of Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID496804	Inhibition of human HDAC4	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID767946	Inhibition of human recombinant HDAC9 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1731759	Inhibition of recombinant human HDAC1 using Ac-LGK(Ac)-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 90 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1236450	Inhibition of human HDAC6	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1525778	Inhibition of HADC2 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID767947	Inhibition of human recombinant HDAC8 protein using RHKAcKAc from p53 as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1684893	Inhibition of HDAC6 in human HL-60 cells assessed as increase in acetylated alpha tubulin level at 0.5 uM after 24 hrs by Western blot analysis
AID1882466	Inhibition of HDAC3 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1384208	Inhibition of HDAC3 (unknown origin)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID772634	Inhibition of human recombinant HDAC5 using acetyl-Lys(trifluoroacetyl)-AMC as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID496803	Inhibition of human HDAC3	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1236451	Inhibition of human HDAC10	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1525777	Inhibition of HADC1 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1819859	Inhibition of full length human HDAC6 using FAM-labeled acetylated peptide as substrate by electrophoretic mobility shift assay	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
AID1882457	Inhibition of HDAC2 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1783141	Inhibition of HDAC10 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1882462	Inhibition of HDAC6 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID772632	Inhibition of human recombinant HDAC8 using RHKAcKAc as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID622268	Selectivity ratio of IC50 for HDAC1 to IC50 for HDAC6	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID1731757	Inhibition of recombinant human HDAC4 using Ac-LGK(TFA)-AMC as substrate pre-incubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1236443	Inhibition of human HDAC2	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID243792	Inhibitory activity against maize histone deacetylase 2 at 40 uM	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID1731766	Inhibition of recombinant human HDAC9 using Ac-LGK(TFA)-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1441631	Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1684902	Induction of apoptosis in human HL-60 cells assessed as early apoptotic cells at 2 uM incubated for 24 hrs by propidium iodide and annexin-V FITC staining based FACS analysis (Rvb = 2.8 %)
AID1783142	Inhibition of HDAC11 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID488277	Inhibition of HDAC8	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID1677972	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1236446	Inhibition of human HDAC4	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1783132	Inhibition of HDAC1 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1684899	Induction of apoptosis in human HL-60 cells assessed as necrotic cells at 2 uM incubated for 24 hrs by propidium iodide and annexin-V FITC staining based FACS analysis (Rvb = 0.3 %)
AID772635	Inhibition of human recombinant HDAC6 using RHKKAc as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID1783134	Inhibition of HDAC3 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1441700	Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS at 10 uM preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID767953	Inhibition of human recombinant HDAC2 protein using RHKKAc from p53 as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID767954	Inhibition of human recombinant HDAC1 protein using RHKKAc from p53 as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID241538	Inhibitory concentration against maize histone deacetylase 1-B (class I HDAC)	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID1173499	Inhibition of full length GST-tagged human HDAC1 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1525776	Inhibition of HADC6 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1525779	Inhibition of HADC3 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID496805	Inhibition of human HDAC5	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1236444	Inhibition of human HDAC3	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID772637	Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID447998	Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
AID1532658	Selectivity ratio of IC50 for human HDAC1 to IC50 for human HDAC6	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Highly fluorescent and HDAC6 selective scriptaid analogues.
AID772654	Inhibition of human recombinant HDAC1 using RHKKAc as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID1572343	Selectivity ratio of IC50 for recombinant C-terminal His/FLAG-tagged human HDAC1 to IC50 for N-terminal GST-tagged human HDAC6	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID241537	Inhibitory concentration against maize histone deacetylase 1-A (class IIa HDAC)	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID1384206	Inhibition of HDAC1 (unknown origin)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID496808	Activity of human HDAC8	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1882467	Inhibition of HDAC8 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID367242	Selectivity ratio of IC50 for human recombinant histone deacetylase 8 to IC50 for human recombinant histone deacetylase 6	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3	Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID1236447	Inhibition of human HDAC5	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1783140	Inhibition of HDAC9 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1384209	Inhibition of HDAC6 (unknown origin)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID367236	Induction of histone H3 acetylation in human T24 cells	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3	Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID90679	Inhibition of Histone deacetylase 1 induced acetylated histone in mammalian cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1384207	Inhibition of HDAC2 (unknown origin)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1173504	Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1173500	Inhibition of full length C-terminal 6x-His tagged human HDAC2 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1677973	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with high 200 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1783135	Inhibition of HDAC4 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1236442	Inhibition of human HDAC1	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1236448	Inhibition of human HDAC7	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1731758	Inhibition of recombinant human HDAC7 using Ac-LGK(TFA)-AMC as substrate pre-incubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1236449	Inhibition of human HDAC9	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1236452	Inhibition of human HDAC11	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1783138	Inhibition of HDAC7 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID512609	Inhibition of HDAC6 in human A549 cells assessed as induction of alpha-tubulin acetylation by fluorescence microscopy	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
AID385231	Inhibition of HDAC9	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
AID1677974	Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and high 20 uM FAS incubated for 35 mins by MS analysis	2020	Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID767944	Inhibition of human recombinant HDAC11 protein using RHKKAc from p53 as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1783133	Inhibition of HDAC2 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID772638	Inhibition of human recombinant HDAC2 using RHKKAc as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID1684901	Induction of apoptosis in human HL-60 cells assessed as late apoptotic cells at 2 uM incubated for 24 hrs by propidium iodide and annexin-V FITC staining based FACS analysis (Rvb = 4.8 %)
AID385229	Inhibition of HDAC1	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
AID1572341	Inhibition of recombinant C-terminal His/FLAG-tagged human HDAC1 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID239791	Selectivity for class IIa HDACs as ratio of IC50 for maize histone deacetylase 1-B and 1-A	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID1173503	Inhibition of C-terminal 6x-His tagged human HDAC5 (657 to 1123 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID488276	Inhibition of HDAC6	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID1783137	Inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID772650	Inhibition of HDAC6 in human HeLa cells using acetyl tubulin as substrate assessed as Ac-Lys accumulation in nuclear histones after 6 hrs by immunofluorescence assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID1441699	Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA at 10 uM preincubated for 10 mins followed by substrate addition measured after 10 mins	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1882456	Inhibition of HDAC1 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1173502	Inhibition of N-terminal GST-tagged human HDAC4 (627 to 1085 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1731764	Inhibition of recombinant human HDAC6 using Boc-Lys(Ac)-AMC as substrate pre-incubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID496806	Inhibition of human HDAC6	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1731763	Inhibition of recombinant human HDAC5 using Ac-LGK(TFA)-AMC as substrate pre-incubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1783139	Inhibition of HDAC8 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID767951	Inhibition of human recombinant HDAC4 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1441632	Binding affinity to recombinant human LTA4H hydrolase assessed as change in melting temperature at 50 uM by SYPRO orange dye-based thermofluor assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1798196	Enzyme Inhibition Assay from Article 10.1021/jm7015254: \\Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors.\\	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346032	Human histone deacetylase 6 (3.5.1.- Histone deacetylases (HDACs))	2003	Proceedings of the National Academy of Sciences of the United States of America, Apr-15, Volume: 100, Issue:8	Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (15.84)	29.6817
2010's	65 (64.36)	24.3611
2020's	20 (19.80)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	4 (3.92%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	98 (96.08%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
butyric acid Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.	3.51	1	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
carbamates [no description available]	2.66	2	amino-acid anion
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.13	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	3.41	1	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
bufexamac Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.	3.18	1	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
caffeine [no description available]	2.21	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.31	1	aromatic ether; nitrile; polyether; tertiary amino compound
celecoxib [no description available]	2.15	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
ci 994 tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.	2.05	1	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	4.38	5	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	2.25	1
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.13	1	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide: structure in first source. 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide : A benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines.	2.59	2	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
nocodazole [no description available]	2.07	1	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
entinostat [no description available]	4.71	8	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.11	1	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
ppm 18 [no description available]	3.18	1	naphthoquinone
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.21	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
pyroxamide [no description available]	2.05	1	aromatic amide
suberoyl bis-hydroxamic acid suberoyl bis-hydroxamic acid: antineoplastic, Histone Deacetylase inhibitor	2.05	1	hydroxamic acid
scriptaid scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source	3.05	4	isoquinolines
4-phenylbutyric acid, sodium salt sodium phenylbutyrate : The organic sodium salt of 4-phenylbutyric acid. A prodrug for phenylacetate, it is used to treat urea cycle disorders.	3.51	1	organic sodium salt	EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector; neuroprotective agent; orphan drug; prodrug
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	6.12	21	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfaphenazole Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.	2.21	1	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	2.21	1	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
corticosterone [no description available]	2.15	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
isoflurophate Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.	2.15	1	dialkyl phosphate
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.46	2	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.1	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	2.05	1	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.66	2	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.13	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	3.31	6	diazine; pyrazines	Daphnia magna metabolite
2,4-pyridinedicarboxylic acid lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4.	2.25	1	pyridinedicarboxylic acid
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	2.55	2
alpha-naphthoflavone alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).	2.21	1	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor
c.i. 42510 Rosaniline Dyes: Compounds that contain the triphenylmethane aniline structure found in rosaniline. Many of them have a characteristic magenta color and are used as COLORING AGENTS.. basic fuchsin : A four-component mixture of chemically related dyes comprising pararosanilin, rosanilin, magenta II and new fuchsin in varying amounts. rosanilin : A hydrochloride that is the monohydrochloride of 4-[(4-aminophenyl)(4-iminocyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline. One of the major constituents of Basic fuchsin, together with pararosanilin, magenta II and new fuchsin.	2.08	1
vinblastine [no description available]	2.05	1
l 451167 L 451167: structure given in first source	2.08	1
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.21	1	copper group element atom; elemental gold
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.13	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.05	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
ubenimex ubenimex: growth inhibitor	2.15	1
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.08	1	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
homocysteine Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.	2.05	1	amino acid zwitterion; homocysteine; serine family amino acid	fundamental metabolite; mouse metabolite
cobalt Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.	2.31	1	cobalt group element atom; metal allergen	micronutrient
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.47	2	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
tadalafil [no description available]	2.17	1	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
anacardic acid anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor. anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.	2.13	1	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite
homocysteic acid homocysteic acid: promotes growth in hypophysectomized rats; RN given refers to parent cpd. homocysteic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group has benn oxidised to the corresponding sulfonic acid.. L-homocysteic acid : A homocysteic acid with L-configuration.	2.05	1	homocysteic acid	NMDA receptor agonist
bortezomib [no description available]	3.45	7	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
trapoxin a trapoxin B: from Helicoma ambiens; structure given in first source	2.02	1
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	3.07	4
5'-methylthioadenosine 5'-methylthioadenosine: structure. 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.	2.13	1	thioadenosine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.21	1	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	6.22	24	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	3.51	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	2.21	1	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	3.07	4	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
tamoxifen [no description available]	2.47	2	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
methyl-thiohydantoin-tryptophan methyl-thiohydantoin-tryptophan: structure in first source	2.11	1	organonitrogen compound; organooxygen compound
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.13	1	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
sodium butyrate [no description available]	2.02	1	organic sodium salt	EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
purmorphamine purmorphamine: structure in first source. purmorphamine : A member of the class of purines that is purine substituted at C-2 by a 1-naphthyloxy group, at C-4 by a 4-morpholinophenylamino group, and at N-9 by a cyclohexyl group.	3.12	1	aromatic ether; morpholines; purines; secondary amino compound	osteogenesis regulator; SMO receptor agonist
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: structure in first source. alvespimycin : A 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group.	2.59	2	1,4-benzoquinones; ansamycin; carbamate ester; secondary amino compound; tertiary amino compound	Hsp90 inhibitor
fexaramine fexaramine: structure in first source	3.12	1	biphenyls
romidepsin depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.	2.44	2	cyclodepsipeptide; heterocyclic antibiotic; organic disulfide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
bleomycin [no description available]	2.25	1	bleomycin	antineoplastic agent; metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.31	1	cysteinium	fundamental metabolite
bafilomycin a [no description available]	2.11	1
laq824 LAQ824: Histone deacetylase inhibitor	2.48	2
tanespimycin CP 127374: analog of herbimycin A	2.1	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone [no description available]	2.74	3	oligopeptide
belinostat [no description available]	3.23	5	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	4.52	6	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42 HDAC-42: structure in first source	2.31	1	amidobenzoic acid
tws 119 [no description available]	3.12	1	pyrroles
givinostat [no description available]	2.79	3	carbamate ester
sc 57461 SC 57461: a leukotriene A4 hydrolase inhibitor; structure given in first source	2.15	1
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.25	1	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
cabazitaxel cabazitaxel: an antineoplastic agent; structure in first source. cabazitaxel : A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.	2.13	1	tetracyclic diterpenoid	antineoplastic agent; microtubule-stabilising agent
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.49	2	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
spiruchostatin a spiruchostatin A: a potent histone deacetylase inhibitor; structure in first source	2.25	1
erastin erastin: an antineoplastic agent; structure in first source. erastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer.	2.31	1	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor
abt-737 [no description available]	2.25	1	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
cardiogenol c cardiogenol C: structure in first source	3.12	1	methoxybenzenes; substituted aniline
quisinostat [no description available]	2.53	2	indoles
resminostat resminostat: a histone deacetylase inhibitor; structure in first source	2.15	1
abexinostat abexinostat: structure in first source	2.53	2	benzofurans
hc toxin [no description available]	2.44	2
lumacaftor lumacaftor: a corrector of CF transmembrane conductance regulator (CTFR); structure in first source. lumacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fibrosis.	2.55	2	aromatic amide; benzodioxoles; benzoic acids; cyclopropanes; organofluorine compound; pyridines	CFTR potentiator; orphan drug
valproate sodium Epilim: oral sodium valproate used as antidepressive agent. sodium valproate : The sodium salt of valproic acid.. valproate : A branched-chain saturated fatty acid anion that is the conjugate base of valproic acid.	2.47	2	organic sodium salt	geroprotector
srt1720 [no description available]	2.11	1
cudc 101 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source	2.15	1
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester CAY10603: a HDAC6 inhibitor	3.96	3	carbamate ester
navitoclax [no description available]	2.25	1	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
plx4032 [no description available]	2.25	1	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	2.25	1	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
tubastatin a [no description available]	6.4	19	hydroxamic acid; pyridoindole; tertiary amino compound	EC 3.5.1.98 (histone deacetylase) inhibitor
pracinostat pracinostat : A hydroxamic acid that is N-hydroxyacrylamide which is substituted at position 3 by a 2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl group (the E isomer). An orally available pan-histone deacetylase inhibitor with demonstrated activity in the treatment of advanced solid tumours.	2.53	2	benzimidazole; hydroxamic acid; olefinic compound; tertiary amino compound	antimalarial; antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
acy-1215 ricolinostat: an HDAC6 inhibitor; structure in first source	5.5	10	pyrimidinecarboxylic acid
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.31	1	benzenes; hydroxycoumarin; methyl ketone
rg2833 RG2833: a histone deacetylase inhibitor; structure in first source	2.15	1
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.07	1
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.13	1
acy-738 [no description available]	3.78	2
2-((1-(3-fluorophenyl)cyclohexyl)amino)-n-hydroxypyrimidine-5-carboxamide [no description available]	3.78	2
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide 4-((1-butyl-3-phenylureido)methyl)-N-hydroxybenzamide: inhibits HDAC6; structure in first source	2.66	2
1,2-bis(isothiazol-5-yl)disulfane 1,2-bis(isothiazol-5-yl)disulfane: structure in first source	2.13	1
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.17	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	2.17	1	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	2.15	1
6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidin-4-one [no description available]	3.41	1

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	2.77	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.77	3
Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.	3	1
African Sleeping Sickness [description not available]	2.11	1
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	2.11	1
Cryptogenic Fibrosing Alveolitis [description not available]	2.15	1
Lung Injury, Acute [description not available]	2.15	1
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	2.15	1
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	2.15	1
Acute Confusional Senile Dementia [description not available]	3.73	3
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	3.73	3
Orphan Diseases Rare diseases that have not been well studied.	2.25	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.53	7
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Cystic Fibrosis of Pancreas [description not available]	3.33	1
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	3.33	1
Bladder Cancer [description not available]	2.83	3
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.83	3
Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.	2.6	1
Fundus Flavimaculatus [description not available]	2.55	2
Age-Related Macular Degeneration [description not available]	2.55	2
Stargardt Disease A juvenile-onset macular dystrophy characterized by progressive loss of VISUAL ACUITY with normal acuity in peripheral VISUAL FIELDS. Other associated clinical features may include LIPOFUSCIN fundus autofluorescence, atrophy of the RETINAL PIGMENT EPITHELIUM, loss of color vision, PHOTOPHOBIA and PARACENTRAL SCOTOMA. Germline mutations in the ABCA4 gene have been identified in recessive and dominant diseases.	2.55	2
Macular Degeneration Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.	2.55	2
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.61	2
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.61	2
Gulf War Syndrome [description not available]	2.15	1
Persian Gulf Syndrome Unexplained symptoms reported by veterans of the Persian Gulf War with Iraq in 1991. The symptoms reported include fatigue, skin rash, muscle and joint pain, headaches, loss of memory, shortness of breath, gastrointestinal and respiratory symptoms, and extreme sensitivity to commonly occurring chemicals. (Nature 1994 May 5;369(6475):8)	2.15	1
Astrocytoma, Grade IV [description not available]	2.15	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.15	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.76	3
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.17	1
Retinal Degeneration A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)	2.17	1
Black Fever [description not available]	2.21	1
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	2.21	1
Atherosclerotic Parkinsonism [description not available]	2.21	1
Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)	2.21	1
Thrombopenia [description not available]	2.21	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.21	1
Breast Cancer [description not available]	2.45	2
Breast Neoplasms Tumors or cancer of the human BREAST.	2.45	2
Aura [description not available]	2.08	1
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	2.08	1
Cyst [description not available]	2.1	1
Liver Dysfunction [description not available]	2.1	1
Liver Diseases Pathological processes of the LIVER.	2.1	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.13	1
Cirrhosis [description not available]	2.13	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.13	1
Benign Neoplasms, Brain [description not available]	2.11	1
Glial Cell Tumors [description not available]	2.11	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.11	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.11	1
ADPKD [description not available]	2.13	1
Polycystic Kidney, Autosomal Dominant Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.	2.13	1
Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans [description not available]	2.13	1
Dwarfism, Thanatophoric [description not available]	2.13	1
Achondroplasia An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, GENU VARUM, and trident hand. (Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim, MIM#100800, April 20, 2001)	2.13	1
Cancer of Prostate [description not available]	2.49	2
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.49	2
Kahler Disease [description not available]	2.46	2
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.46	2
African Lymphoma [description not available]	2.05	1
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	2.05	1
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	7.05	1
Disease Exacerbation [description not available]	2.06	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.06	1
Acute Lymphoid Leukemia [description not available]	2.47	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.47	2
Invasiveness, Neoplasm [description not available]	2.07	1

tubacin

Description

Cross-References

Synonyms (39)

Research Excerpts

Overview

Treatment

Bioavailability

Drug Classes (1)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (209)

Molecular Functions (73)

Ceullar Components (47)

Bioassays (163)

Research

Studies (101)

Market Indicators

Research Demand Index: 32.68

Study Types

tubacin

Description

Cross-References

Synonyms (39)

Research Excerpts

Overview

Treatment

Bioavailability

Drug Classes (1)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (209)

Molecular Functions (73)

Ceullar Components (47)

Bioassays (163)

Research

Studies (101)

Market Indicators

Research Demand Index: 32.68

Study Types

Related Drugs (113)

Related Conditions (70)